Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis

Circulation

Volumn 100, Issue 15, 1999, Pages 1616-1622

  Strauss, Bradley H ^a   Lau, Herbert K ^a   Bowman, Kimberley A ^a   Sparkes, John ^a   Chisholm, Robert J ^a   Garvey, M Bernadette ^a   Fenkell, Louis L ^a   Natarajan, Madhu K ^a   Singh, Inderbir ^a   Teitel, Jerome M ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Angioplasty; Fibrinolysis; Restenosis; Urokinase

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0032830147     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.15.1616     Document Type: Article

References (29)

1. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267-274.
2. Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation. 1990;82:2190-2200.
3. Clowes AW, Clowes MM, Au YPT, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res. 1990; 67:61-67.
4. Reidy MA, Irvin C, Lindner V. Migration of arterial wall cells: expression of plasminogen activators and inhibitors in injured rat arteries. Circ Res. 1996;78:405-414.
5. Hasenstab D, Forough R, Clowes AW. Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinases-2 increase after arterial injury in rats. Circ Res. 1997;80:490-496.
6. Saksela O, Rifkin D. Cell-associated plasminogen activation: regulation and physiological function. Annu Rev Cell Biol. 1988;4:93-126.
7. Vassalli JD. The urokinase receptor. Fibrinolysis. 1994;8(suppl 1):172-181.
8. Strauss BH, Escaned J, Foley DP, DiMario C, Haase J, Keane D, Hermans WR, Rensing BJ, de Feyter P, Serruys PW. Quantitative coronary angiography (QCA) in interventional cardiology: clinical application of QCA measurements. Prog Cardiovasc Dis. 1994;36:363-384.
9. Adelman AG, Cohen EA, Kimball BP, Bonan R, Ricci DR, Webb JG, Laramee L, Barbeau G, Traboulsi M, Corbett BN, Schwartz L, Logan AG. A comparison of directional atherectomy with balloon angioplasty for lesions of the left anterior descending artery. N Engl J Med. 1993; 329:228-233.
10. Cheung T, Liu AYY, Lau HKF. Characterization of radioimmunoassays against high-and low-molecular weight urokinases and quantitation of different molecular forms of urokinase in urine using these assays. J Lab Clin Med. 1993;121:461-471.
11. Kung SKP, Lau HKF. Modulation of the plasminogen activation system in murine macrophages. Biochim Biophys Acta. 1993;1176:113-122.
12. Angles-Cano E. A spectrophotometric solid-phase fibrin-tissue plasminogen activator assay (SOFIA-tPA) for high-fibrin-affinity tissue plasminogen activators. Anal Biochem. 1986;153:201-210.
13. Masson C, Angles-Cano E. Kinetic analysis of the interaction between plasminogen activator inhibitor-1 and tissue-type plasminogen activator. Biochem J. 1988;256:237-244.
14. Strauss BH. Natarajan MK. Lesion morphology and composition: risk of restenosis following coronary interventions. In: Klein LW, ed. Coronary Stenosis Morphology: Analysis and Implication. Boston, Mass: Kluwer Academic Publishers; 1997:311-339.
15. Kuntz RE Safian RD, Carroza JP, Fischman RF, Mansour M, Baim DS. The importance of acute luminal diameter in determining restenosis after coronary atherectomy or stenting. Circulation. 1992;86:1827-1835.
16. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeimer W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 1992;11:4825-4833.
17. Del Rosso M, Anichini E, Pedersen N, Blasi F, Fibbi G, Pucci M, Ruggeiro M. Urokinase-urokinase receptor interaction: non-mitogenic signal transduction in human epidermal cells. Biochem Biophys Res Commun. 1993;190:347-352.
18. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin αVβ3 binding to vitronectin. Nature. 1996;383:441-443.
19. Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossowski L, Andreasen PA. Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res. 1997;232:420-429.
20. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. Regulation of integrin function by the urokinase receptor. Science. 1996;273:1551-1555.
21. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res. 1996;224:344-353.
22. Waltz DA, Sailor LZ, Chapman HA. Cytokines induce urokinase-dependent adhesion of human myeloid cells: a regulator role for plasminogen activator inhibitors. J Clin Invest. 1993;91:1541-1552.
23. Okada SO, Grobmyer SG, Barnathan ES. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion. Arterioscler Thromb Vasc Biol. 1996;16:1269-1276.
24. Chang AW, Kuo A, Okada SS, Barnathan ES. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase. Arterioscler Thromb Vasc Biol. 1998;18:1855-1860.
25. Carmeliet P, Moons L, Herbert J-M, Crawley J, Lupu F, Lijnen R, Collen D. Urokinase but not tissue plasminogen activator mediates arterial neointimal formation in mice. Circ Res. 1997;81:829-839.
26. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation. 1997;96:3180-3191.
27. Held C, Hjemdahl P, Rehnqvist N, Wallen H, Bjorkander I, Eriksson SV, Forslund L, Wiman B. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol: results from the angina prognosis study in Stockholm. Circulation. 1997;95:2380-2386.
28. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
29. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: a 7-year follow-up. Circulation. 1993;88: 2030-2034.